TCR² is an innovative immunotherapy company developing the next generation of T cell therapies for patients suffering from cancer. Our proprietary TRuC⢠(TCR Fusion Construct) T cells â a novel T cell therapy platform â reprogram the natural T cell receptor complex to recognize and kill cancer cells using the full power of T cell signaling pathways independent of HLA. Source
No articles found.
PLx Pharma Inc. (Nasdaq: PLXP), is a late-stage specialty pharmaceutical company i...
PLx Pharma Inc. (Nasdaq: PLXP), is a late-stage...
EyePoint Pharmaceuticals, Inc. is a specialty biopharmaceutical company committed ...
EyePoint Pharmaceuticals, Inc. is a specialty b...
Mirati Therapeutics (NASDAQ: MRTX) is a San Diego-based clinical-stage biotechnolo...
Mirati Therapeutics (NASDAQ: MRTX) is a San Die...
Emerald Health Pharmaceuticals (EHP) combines decades of life science and drug dev...
Emerald Health Pharmaceuticals (EHP) combines d...
Stoke is pioneering a new way to treat the underlying cause of severe genetic dise...
Stoke is pioneering a new way to treat the unde...
China Biologic Products Holdings, Inc. (NASDAQ: CBPO), is a leading fully integrat...
China Biologic Products Holdings, Inc. (NASDAQ:...
OncoSec Medical Incorporated is a clinical-stage biotechnology company focused on ...
OncoSec Medical Incorporated is a clinical-stag...
Merus is a clinical-stage immuno-oncology company developing innovative full-lengt...
Merus is a clinical-stage immuno-oncology compa...
NextCure is a clinical-stage biopharmaceutical company committed to discovering an...
NextCure is a clinical-stage biopharmaceutical ...
Genocea is a biopharmaceutical company developing personalized cancer immunotherap...
Genocea is a biopharmaceutical company developi...
Join the National Investor Network and get the latest information with your interests in mind.